Key facts
- This page summarizes Joshua R. Lamstein's Form 4 filing for Scopus BioPharma Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 26 Nov 2021, 16:01.
Joshua R. Lamstein - 23 Nov 2021 Form 4 Insider Report for Scopus BioPharma Inc.
- Reporting relationship
- Chairman, Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 23 Nov 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Nov 2021, 16:01:05 UTC
- Prior SEC filing
- 27 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joshua R. Lamstein
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Joshua R. Lamstein filed Form 4 for Scopus BioPharma Inc. on 26 Nov 2021.
Change
- Previous filing in this sequence was filed on 27 Aug 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SCPS
transaction
Derivative
W Warrants
Other
- Transaction value
- Shares
- -3,000,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 23 Nov 2021
- Ownership
- HCFP/Capital Partners 18B-2 LLC
- Underlying class
- B Unit
- Underlying amount
- 3,000,000
- Exercise price
- $4.00
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The Reporting Person is a member and co-manager of HCFP/Capital Partners 18B-2 LLC ("HCFP 18B-2"). On November 23, 2021, HCFP 18B-2, pursuant to a Warrant Contribution Agreement by and between the Issuer and HCFP 18B-2, agreed to contribute its 3,000,000 W Warrants back to the Company in exchange for the Company cancelling a $1.5 million contingent promissory note, including any and all interest, owed by HCFP 18B-2 to the Company.